for LA, aCL (IgG/IgM), anti- β 2GPI antibodies (IgG/IgM) were present in the group that developed myocardial infarction (Chi square test: $p < 0.05$ for all aPL) (Table 2).

Conclusions: The aGAPSS is based upon a quantitative score and could aid risk stratifying APS patients younger than 50 years for the likelihood of developing coronary thrombotic events and may consequently guide pharmacological treatment for high-risk patients.

References:

- [1] Zimmerman FH, Cameron A, Fisher LD, Ng G. Myocardial infarction in young adults: angiographic characterization, risk factors and prognosis (Coronary Artery Surgery Study Registry). *J Am Coll Cardiol* 1995;26:654–61.
- [2] Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: the Global Anti-Phospholipid Syndrome Score. *Rheumatology* (Oxford) 2013;52:1397–403. doi:10.1093/rheumatology/kes388.

Acknowledgements: None.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1600

FRI0717 POSITIVE CONVERSION OF TUBERCULOSIS SCREENING RESULTS AND INCIDENCE OF ACTIVE TUBERCULOSIS INFECTION IN PATIENTS RECEIVING BIOLOGIC TREATMENT

M.-C. Park¹, H.W. Kim¹, S.H. Han². ¹Division of Rheumatology; ²Division of Infectious Diseases, Yonsei University College of Medicine, Seoul, Korea, Republic Of

Background: Previous studies reported active tuberculosis infections can occur during biologic treatment in patients with negative baseline LTBI screening. Current recommendations suggesting the annual testing for latent tuberculosis infections are mainly issued for patients with rheumatoid arthritis (RA) receiving anti-TNF inhibitors and there are lacking evidence for patients receiving non-TNF biologic agents and for patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA).

Objectives: This study was performed to investigate the conversion rate of initially negative tuberculosis screening test results during biologic treatment and the usefulness of repeated screening test for detecting unexpected tuberculosis infection in patients with RA, AS, and PsA.

Methods: A total of 95 patients (43 with RA, 50 with AS, and 2 with PsA) who had negative baseline interferon γ releasing assay (IGRA) results, which were assessed using QuantiFERON-TB Gold in tube (QTF-GIT), prior to initiation of biologic treatment were enrolled in this study. All patients received biologic agents for the treatment of their diseases and rescreening with QTF-GIT were performed in all patients after median 12 months from baseline test. Clinical characteristics were compared between converters and non-converters and incidence of active tuberculosis infection was evaluated.

Results: Patients were treated with different biologics (23 with etanercept, 50 with adalimumab, 5 with infliximab, 4 with golimumab, 1 with certolizumab pegol, 3 with abatacept, and 9 with tocilizumab). Positive conversions of initially negative IGRA were found in 13 (6 patients with etanercept, 4 patients with adalimumab, 2 patients with tocilizumab and 1 patient with abatacept) of 95 patients (13.7%) after initiation of biologic treatment. Age over 50 years and diagnosis of RA were more common in converters. Multivariate analysis showed that age over 50 was an independent risk factor for IGRA conversion with OR 4.36 (95% CI 1.10 - 17.34, $p=0.036$). During biologic treatments, active tuberculous infections were found in 3 of 13 converters (23.1%).

Conclusions: Although initial screening test showed negative results, the serial follow-up of tuberculosis screening test should be considered during biologic treatment in patients with rheumatic diseases to prevent unexpected tuberculosis infection.

References:

- [1] Hatzara C, Hadziyannis E, Kandili A, Koutsianas C, Makris A, Georgiopoulos G, et al. Frequent conversion of tuberculosis screening tests during anti-tumour necrosis factor therapy in patients with rheumatic diseases. *Ann Rheum Dis* 2015;74:1848–53.
- [2] Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF α inhibitors: the utility of IFN γ assay. *Ann Rheum Dis* 2012;71:231–7.
- [3] Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. *Arthritis Care Res* 2012;64:625–39.

Acknowledgements: This study was supported by a grant of the Korean Health Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (H14C1774).

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.1286

FRI0718 PREVALENCE AND PATTERN OF COMORBIDITIES IN CHRONIC RHEUMATIC AND MUSCULOSKELETAL DISEASES: THE COMORD STUDY

N.R. Ziade^{1,2}, F. Fayad^{1,2}, B. Khoury³, M. Zoghbi⁴, G. Merheb⁵, G. Abi karam^{1,2}, K. Mroue⁶, J. Missaykeh⁷. ¹Rheumatology, Hotel Dieu de France; ²Rheumatology; ³Medicine; ⁴Family Medicine, St-Joseph University, Beirut; ⁵Medicine, ND des Secours, Jbeil; ⁶Rheumatology, Zahra University Hospital, Beirut; ⁷Rheumatology, Monla Hospital, Tripoli, Lebanon

Background: Rheumatic and musculoskeletal diseases (RMD) frequently coexist with other conditions, resulting in multimorbidity, which may compromise arthritis management and lead to diminished quality-of-life and increased mortality. In 2016, EULAR published "Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases", used to guide this study.

Objectives: The primary objective is to evaluate the prevalence and pattern of comorbidities in selected RMD in Lebanese patients. The secondary objective is to evaluate the gap between recommendations and routine comorbidities' screening.

Methods: COMORD is an observational, cross-sectional, multicentric national study. Consecutive RMD patients (Rheumatoid Arthritis (RA), Osteoarthritis (OA), Systemic Lupus Erythematosus (SLE), Axial Spondyloarthritis (AxSpA) and Peripheral Spondyloarthritis (pSpA)) as diagnosed by the rheumatologist were recruited at 6 practices from university hospitals and private clinics in Lebanon. Six axes of comorbidities (Cardiovascular, Malignancies, Infections, Gastrointestinal, Osteoporosis, Depression) were investigated using a case report form (patient interview). Optimal comorbidities screening was defined according to current recommendations and compared with monitoring in practice. Prevalences were presented descriptively. The number of comorbidities was correlated with predictive factors using Poisson Regression. Finally, Latent Class Analysis (LCA) was used to identify patterns of multimorbidity. All analysis were performed on IBM SPSS Statistics 23 and XLSTAT 18.07.

Results: 515 patients were recruited (196 RA, 161 OA, 75 AxSpA, 45 SLE, 40 pSpA). Mean age was 56y, 76% were female. There was no difference in the disease distribution between centers. The most common comorbidities were cardiovascular risk factors and diseases, followed by depression and osteoporosis. The number of comorbidities was significantly associated with age ($p < 0.001$), obesity ($p < 0.001$) and biotherapies ($p < 0.05$). LCA analysis identified 3 main clusters of multimorbidity: OA, RA, AxSpA (Fig 1). The most optimal screening was found for cardiovascular risk factors (84%). DXA was prescribed in 69% of correct indications. As for malignancies, mammograms and pap smears were the most optimally prescribed (36% and 28%). Colonoscopy and dermatology visit were prescribed in 22% and 18%. Correct vaccination (influenza and pneumococcal) was found in 17% and 8%. Predictive factors for optimal screening were age, university setting, social coverage, disease duration and biotherapy.

Figure 1. Identified Multimorbidity Clusters by Latent Class Analysis

Conclusions: Comorbidities are prevalent in RMDs and follow specific multimorbidity patterns, with a predominance for cardiovascular, depression and osteoporosis. They are more frequent with age and obesity. Optimal screening needs to be improved.

References:

- [1] Baillet et al. *Ann Rheum Dis* 2016.
- [2] Dougados et al. *Ann Rheum Dis* 2014.

[3] Molto et al. Ann Rheum Dis 2016.

[4] Simoes et al. Arthritis Care & Research 2017.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.2186

FRI0719 BURDEN OF HEPATITIS E VIRUS INFECTION IN PATIENTS WITH RHEUMATIC DISEASES

P. Jacques^{1,2}, E. Padalko³, E. Verheugen^{1,2}, L. Cattoir³, X. Verhelst⁴, E. Nys³, S. Van Gucht⁵, V. Hutse⁵, V. Suin⁵, D. Elewaut^{1,2}. ¹Rheumatology, University Hospital; ²VIB, Ghent University; ³Clinical Chemistry, Microbiology and Immunology; ⁴Gastroenterology, University Hospital, Ghent; ⁵National Reference Centre for Viral Hepatitis, Scientific Institute of Public Health, Brussels, Belgium

Background: Hepatitis E virus (HEV) is considered an emerging pathogen in developed countries, potentially causing chronic hepatitis.

Objectives: This cross-sectional analysis was undertaken to determine the seroprevalence of HEV in patients with autoimmune or inflammatory arthritis. This subgroup of patients is often treated with immune suppressive drugs, and is generally considered more susceptible to infections.

Methods: Serum samples were obtained from 449 consecutive patients consulting at the department of Rheumatology between October and November 2015. Patient characteristics with respect to diagnosis and treatment were collected. HEV IgM and IgG were measured by ELISA (Wantai Hepatitis E Virus IgG and IgM ELISA, Sanbio BV). Positive or borderline samples were further analyzed for HEV RNA (RealStar[®] HEV RT-PCR Kit, Altona Diagnostics NRC WIV).

Results: A total of 449 patients were included, 211 men and 238 women. HEV IgG was positive in 82 samples (18.26%), 6 were borderline, and 5 were non-determinable (not enough serum). IgM was positive in only 2 samples (0.45%). These 2 patients had normal liver function tests. Additional PCR was performed on all positive and borderline samples, which turned out negative in all samples. Of the 88 IgG positive and borderline samples, 86 patients had a known diagnosis of chronic inflammatory arthritis, of which 50 patients had previously been diagnosed with rheumatoid arthritis, 18 with spondyloarthritis, 8 with psoriatic arthritis. Fifty patients were treated with biologics (37 TNF inhibitors), 43 patients were treated with methotrexate (mean dose 12.5mg weekly), and 20 were treated with corticosteroids (mean daily dose 5.5mg prednisolone equivalent).

Conclusions: In a consecutive cohort of patients with known diagnosis of autoimmune or inflammatory arthritis, seroprevalence of HEV IgG was 18.2%. No active HEV infection could be detected. We found this to be comparable to a historical cohort of healthy patients from the departments of Orthopedics and obstetrics¹, where prevalence of HEV IgG was 14%.

References:

[1] Van Hoecke F et al. Acta Gastroenterol Belg. 2012 Sep;75(3):322-4.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5115

FRI0720 CHARACTERISTICS OF PATIENTS WITH GOUT TREATED TO SUA TARGET THAT CONTINUE TO EXPERIENCE FLARES: DATA FROM FRANCE, GERMANY, ITALY, SPAIN, UK AND US

R. Morlock¹, D.C. Taylor², S. Baumgartner³. ¹YourCareChoice, Ann Arbor; ²Health Economics and Outcomes Research, Ironwood Pharmaceuticals, Cambridge; ³drB Consulting, Spokane, United States

Background: Gout is a common form of inflammatory arthritis. Treatment guidelines recommend a target serum urate (sUA) ≤ 6 mg/dL. ACR and EULAR treatment guidelines indicate sUA targets may need to be surpassed to achieve treatment benefits in a subset of patient that continue to flare and/or have tophi.

Methods: Data were assessed from a survey of physicians about gout disease management. Patient results were confirmed through in-depth chart audits assessing diagnosis, comorbid conditions, disease severity and laboratory assessments. Disease severity was measured using a physician global assessment, flare counts, joint damage and presence of tophi. Type and dose of XOI, length of current treatment, compliance, physician type and patient socio-demographic factors were identified. Descriptive and multivariate statistics were used to describe patients having ≥ 2 flares per year (excluding treatment-related flares) in patients achieving target sUA ≤ 6 mg/dL.

Results: Overall, 251 rheumatologists and 250 primary care physicians were interviewed and provided data from 2505 patients with gout; 82% were male and the average age was 58 years (SD=12). 1823 (73%) patients were treated with an XOI, of these 813 (44%) had a least one assessment of sUA ≤ 6 mg/dL over a 12-month period. Of the 813 patients reaching sUA target, 307 (37.8%) reported ≥ 2 flares in the last year. On average, patients at sUA goal with ≥ 2 flares had been treated over 38.8 months on their current XOI and patients with ≤ 1 flare had been treated for 40.7 months. Patients at sUA ≤ 6 mg/dL treated with an XOI and reporting ≥ 2 flares a year were more likely to have tophi (32.9% vs. 19.2%; $p<0.01$), alcoholism (22.8 vs. 10.7; $p<0.01$), CVD (24.8 vs. 17.6%; $p=0.014$), depression (14.3 vs. 9.3; $p=0.027$), and diabetes mellitus (23.8 vs. 16.8; $p=0.015$) compared to patients with ≤ 1 flare a year. A backward stepwise multivariate model predicting patients classified as controlled (sUA ≤ 6 mg/dL) and continuing to flare (≥ 2 flares in the last year) found the physician-reported and chart-documented comorbidities of chronic kidney disease (OR 1.9; $p<0.01$),

alcoholism (OR 2.4; $p<0.01$), diabetes mellitus (OR 1.5; $p<0.05$), and have tophi (1.7; $p<0.01$) to be associated with having higher flare rates despite achieving sUA ≤ 6 mg/dL. There was no difference by the type of XOI or physician.

Conclusions: Of the patients achieving target sUA level of ≤ 6 mg/dL, 62% have ≤ 1 flare; however, over a third reported ≥ 2 in a 12-month period. Patients with multiple flares were more likely to have higher urate burden in the form of tophi, chronic kidney disease, alcoholism, and diabetes mellitus comorbid conditions. Frequent flares and greater tophaceous burden may require treating more aggressively to an sUA level of 5 mg/dL or lower as recommended by treatment guidelines.

Acknowledgements: This study was funded by Ironwood Pharmaceuticals.

Disclosure of Interest: R. Morlock Consultant for: Ironwood Pharmaceuticals, D. Taylor Employee of: Ironwood Pharmaceuticals, S. Baumgartner Consultant for: Ironwood Pharmaceuticals

DOI: 10.1136/annrheumdis-2017-eular.6142

FRI0721 SLEEP DISORDERS IN PATIENTS AT THE FIRST ACCESS TO A RHEUMATOLOGY OUTPATIENT CLINIC

R. Tirri, D. Capocotta, R. Ferrara. Department of internal and experimental Medicine, Unit of Rheumatology of University of study of Campania "Luigi Vanvitelli", Naples, Italy

Background: Sleep disturbances are frequently found in patients affected by rheumatic conditions (1). Chronic pain, the most common manifestation of these conditions is associated to poor sleep (2).

Objectives: Our primary objective was to evaluate prevalence of excess daytime sleepiness and impaired sleep quality in a patient population at the first access to a Rheumatology outpatient clinic. Secondary objective was evaluation of pain and others factors well known to be associated to sleep disorders.

Methods: 961 out of 1454 (mean age was 52.6 years; 14.3% were male) consecutive patients admitted for the first time to an Italian Rheumatology Outpatient Clinic, between December 2014 and November 2016, accepted to answer a self-administered questionnaire study. We considered the following parameters: pain intensity on visual analogic scale ranging from 0 to 100 according to commonly used classification (3), patient's assessment of General Health (GH), Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), Health Assessment Questionnaire (HAQ), and Body Mass Index (BMI). Smoke habits were also considered.

Results: 70 patients showed both sleep disorders (7.3%), 624 patients had only impaired sleep quality (64.9%), 25 showed isolated excessive daytime sleepiness (2.6%). 242 patients did not have any sleep disorders (25.2%). We found that the presence of both ESS ≥ 10 and PSQI ≥ 5 was correlated to moderate-severe pain VAS pain ≥ 40 , BMI ≥ 35 , HAQ ≥ 1 and GH ≥ 50 with a statistical significance (respectively $p=0.004$; $p=0.032$; $p=0.0004$; $p=0.0001$). A correlation with GH ≥ 50 in the patient group with only PSQI ≥ 5 was detected ($p=0.03$). Smoke habits did not correlate with sleep disturbance measures investigated. No other correlations were found in the other groups.

Conclusions: Thus excess daytime sleepiness and impaired sleep quality may be a target of therapeutic intervention in the treatment of rheumatic conditions. Further studies are needed to generalize results and suggestions.

References:

[1] Generaal E, Vogelzangs N, Penninx WJH, Dekker J. Insomnia, sleep duration, depressive symptoms, and the onset of chronic multisite musculoskeletal pain. Sleep 2017; 40.

[2] Vivien C Abad, Priscilla S.A. Sarinas, Christian Guilleminault. Sleep and rheumatologic disorders. Sleep Medicine Reviews 2008; 12: 211-228.

[3] Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of post-operative pain. J Pain 2003;4:407-14.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.6313

FRI0722 CROSS-SECTIONAL ASSOCIATIONS BETWEEN DEMOGRAPHIC, JOB RELATED, HEALTH RELATED AND PSYCHOSOCIAL FACTORS AND THREE DIFFERENT MEASURES OF PRESENTEEISM: RESULTS FROM EULAR-PRO AT-WORK PRODUCTIVITY STUDY

S. Leggett¹, D. Lacaille², A. Boonen³, C. Mihai⁴, S. Talli⁵, S. Hagel⁶, S. Dadoun⁷, S. Ramiro⁸, A. Bosworth⁹, G. Sakellariou¹⁰, S. Verstappen^{1,11} on behalf of EULAR-PRO at-work productivity co-investigators. ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom; ²University of British Columbia, Vancouver, Canada; ³Maastricht UMC, Maastricht, Netherlands; ⁴Dr. Ion Cantacuzino Hospital, Bucharest, Romania; ⁵East Tallinn Central Hospital, Tallinn, Estonia; ⁶Lund University and Skane University hospital, Lund, Sweden; ⁷APHU Pitie-Salpêtrière Hospital, Paris, France; ⁸Leiden UMC, Leiden, Netherlands; ⁹NRAS, Maidenhead, United Kingdom; ¹⁰IRCCS Policlinico San Matteo Foundation, Pavia, Italy; ¹¹NIHR Manchester Musculoskeletal BRU, Central Manchester NHS Trusts, Manchester, United Kingdom

Background: Several measures of at-work productivity loss (i.e. presenteeism)